2024-513894-35-00招募中2 期
OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 180
- 试验地点
- 4
- 主要终点
- Change from baseline with respect to the total score of the investigator-rated Bech 6-item subscale of the Hamilton Depression Rating Scale (HDRS) at endpoint (10).
研究概览
简要总结
To assess the effect and tolerability of adding OSU6162 to ongoing treatment with a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitor (SNRI) in patients with SSRI/SNRI-resistant depression.
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent.
- •Age: 25-65 on the day of screening.
- •Meeting DSM-5 criteria for major depressive disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI).
- •A symptom-free period preceding the current episode within the past two years confirmed at interview.
- •Not significantly improved, as judged by both doctor and patient, after having been treated with one of the following SSRIs/SNRIs: citalopram, escitalopram, paroxetine, sertraline, fluoxetine, duloxetine, or venlafaxine for at least 6 weeks.
- •Displaying a sum score of MADRS ≥
- •In women of childbearing potential (WOCBP): negative result of a pregnancy test and a method of contraception with a failure rate of less than 1 %. Contraception must be used during the treatment and follow-up period. Acceptable forms of contraception are: a) Use of combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation - oral - intravaginal - transdermal b) progestogen-only hormonal contraception associated with inhibition of ovulation: - oral - injectable - implantable c) Placement of intrauterine device (IUD) or intrauterine hormone releasing system (IUS) d) Bilateral tubal occlusion or ligation e) Vasectomised partner (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate and provided that male partner is the sole sexual partner of the WOCBP trial participant). f) Sexual abstinence.
- •Male patients must agree to use condoms during the study and for 2 weeks after the end of the study/last dose of IMP, unless their partner is using a highly efficient method of contraception, as described above.
排除标准
- •Meeting MINI criteria at interview for suicidality, manic episode, hypomanic episode, bipolar I, bipolar II, bipolar unspecified, bipolar I with psychotic symptoms, panic disorder (current), agoraphobia, posttraumatic stress disorder, alcohol dependency, alcohol abuse, substance dependency (non-alcoholic), substance abuse (non-alcoholic), psychotic disorders, mood disorders with psychotic features, anorexia nervosa, bulimia nervosa, anorexia nervosa binge eating / purging type, or antisocial personality disorder. Meeting MINI criteria at interview for generalised anxiety disorder, obsessive compulsive disorder or social anxiety (social phobia), unless the present symptoms can predominantly be attributed to a diagnosis of major depressive disorder.
- •A history of substance/alcohol abuse within 2 years prior to screening.
- •A previous diagnosis of a personality disorder, autism spectrum disorder, attention-deficit/hyperactivity disorder, or intellectual disability.
- •Any other previously diagnosed or suspected CNS disorder that according to the investigator renders the patient unsuitable for participation in the trial.
- •Any factor that according to the investigator renders it unlikely that the patient will comply with the instructions regarding treatment, visits etc.
- •Any somatic illness that according to the investigator renders the patient unsuitable for participation in the trial.
- •Any signs or symptoms of somatic illness resulting from assessment of vital signs, physical examination, clinical laboratory tests, and 12-lead ECG that according to the investigator renders the patient unsuitable for participation for safety reasons, including a QTc-time on ECG exceeding 450 ms in men and 460 ms in women.
- •Any change in dosage of said SSRI/SNRI within 4 weeks prior to screening or at any time during the course of the trial.
- •Treatment with any other psychoactive drug than said SSRI/SNRI with the exception of using mirtazapine up to 15 mg for sleep, occasional use of benzodiazepines and benzodiazepine-like anxiolytics or hypnotics and occasional use of antihistaminergic sedatives (without anti-dopaminergic effects) within 4 weeks prior to screening and at any time during the course of the trial.
- •Patients who are receiving concomitant therapy with potent cytochrome P450 enzyme inhibitors (e.g., bupropion, fluvoxamin, ketoconazol, itraconazole, telitromycin, clarithromycin, protease inhibitors, quinidine, and terbinafine).
- •Ongoing treatment with drugs with a narrow therapeutic window where either lower or higher serum levels are potentially harmful (including but not limited to warfarin along with other anticoagulants, digoxin along with other antiarrythmics, anticonvulsants prescribed for treatment of epilepsy, cyclosporine, immunosuppressants, and lithium).
- •Current treatment with any prescribed or OTC drug that according to the investigator renders the subject unsuitable for participation in the trial.
- •Previous intake of OSU
- •Current participation in another clinical trial.
- •Nursing women.
- •Substudy only: Relative and/or absolute contraindications to lumbar puncture and functional Magnetic Resonance Imaging (fMRI), as per clinical practice. This includes ongoing treatment with anticoagulants such as NOAC or warfarin.
结局指标
主要结局
Change from baseline with respect to the total score of the investigator-rated Bech 6-item subscale of the Hamilton Depression Rating Scale (HDRS) at endpoint (10).
Change from baseline with respect to the total score of the investigator-rated Bech 6-item subscale of the Hamilton Depression Rating Scale (HDRS) at endpoint (10).
次要结局
未报告次要终点
研究者
Elias Eriksson
Scientific
University Of Gothenburg
研究点 (4)
Loading locations...
相似试验
招募中
1 期
OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety.DepressionEUCTR2020-005860-69-SEniversity of Gothenburg180
招募中
2 期
OSU6162 as add-on in SSRI/SNRI-resistant DepressionDepressive Disorder, Treatment-ResistantDepressive DisorderDepressive EpisodeRecurrent Depressive DisorderRecurrent DepressionDepressionNCT05641623Göteborg University180
已完成
3 期
Study of Pharmacotherapy of Psychotic DepressionMajor Depressive Disorder With Psychotic FeaturesNCT00056472Weill Medical College of Cornell University259
招募中
2 期
Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy:
a prospective phase II trial2024-518631-11-00Medical University Of Vienna35
已完成
3 期
Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake InhibitorsDepressive DisorderNCT00296517GlaxoSmithKline325